Archive: Company News
Company News: Curetis Announces Change in Curetis USA Inc. Management
— Christopher M. Bernard resigns as President & CEO of Curetis USA Inc. effective August 31, 2018
— Chris D. Emery to succeed as President & CEO of Curetis USA Inc. effective September 1, 2018
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Christopher M. Bernard has informed the Company of his resignation as President and CEO of Curetis USA Inc. and as member of the Curetis N.V. Management Board, effective respectively August 31, 2018.
Company News: Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets
— New Unyvero distribution partnerships in Egypt, Mexico, and Uruguay
— Contractual commitments for 45 Unyvero Systems
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today announced exclusive distribution partnerships in Egypt, Mexico, and Uruguay with Future Horizon Scientific, Quimica Valaner S.A. de C.V., and Biko S.A., respectively. The signing of these agreements follows a systematic qualification process conducted by Curetis, which focused on identifying distributors that are experienced in commercializing innovative products for international molecular diagnostics companies.
Company News: Curetis to Report its Half-Year Results 2018 on August 14, 2018
– Company will host earnings conference call and webcast
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it will publish its financial results for the first six months ended on June 30, 2018, on August 14, 2018. In addition, the Company will host a public conference call and webcast on August 14, 2018, at 12:30 pm CEST / 06:30 am EDT to present the H1-2018 financial results, highlight the most important events and provide an outlook for the second half of 2018 and beyond.
Company News: Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program
— Program aims to counteract antibiotic resistance by use of artificial intelligence in drug development
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the launch of the ARES & CO (Antibiotic RESistance Solutions by COoperative R&D) pharma partnering program by its wholly-owned subsidiary Ares Genetics GmbH based in Vienna, Austria. The program aims at establishing an alliance for antibiotic stewardship with pharmaceutical companies and contract research organizations. The program is supported and largely funded by the Vienna Business Agency.